Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACROBAT Evolve: CRN00808 randomized withdrawal study in acromegaly responders
2018-001833-42Phase 2Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acromegaly comparing CRN00808 arm with Placebo arm (2 arms). Primary endpoint: Biochemical responder rate (IGF-1). Started Sep 2018; status: completed.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2018-001833-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001833-42.